Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dopamine Clear all
Completed Phase 1 Interventional

Measuring Parkinson's Disease Progression

NCT03205956
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Levodopa
Drug
Lead sponsor
Kevin J. Black, MD
Other
Eligibility
40 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Jul 23, 2026, 4:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dopamine Neurotransmission in Major Depression

NCT01659814
View directory record Official record
Conditions
Major Depressive Disorder, Anhedonia
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Jul 23, 2026, 4:05 AM EDT
Enrolling by invitation Phase 3 Interventional

Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder

NCT06878976
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Solriamfetol 75mg, 150 mg, or 300 mg
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 56 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
31
States / cities
Encino, California • Long Beach, California • Santa Ana, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 23, 2026, 4:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Dopamine Receptors in Primary Focal Dystonias

NCT01373840
View directory record Official record
Conditions
Healthy, Focal Dystonias
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Jul 23, 2026, 4:05 AM EDT
Not yet recruiting Phase 4 Interventional

Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide

NCT06740812
View directory record Official record
Conditions
Nausea and Vomiting, Nausea, Vomiting
Interventions
Fosaprepitant for Injection, Metoclopramide Injection
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 4:05 AM EDT
Recruiting Phase 2 Interventional

A Study of Pasireotide in People With Prolactinoma

NCT06295952
View directory record Official record
Conditions
Prolactin-Producing Pituitary Tumor
Interventions
Pasireotide, SF-36 and HADS
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 23, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

Embryonic Dopamine Cell Implants for Parkinson's Disease

NCT00038116
View directory record Official record
Conditions
Parkinson Disease
Interventions
embryonic dopamine cell implant surgery, placebo
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2009
U.S. locations
3
States / cities
Denver, Colorado • Manhasset, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Jul 23, 2026, 4:05 AM EDT
Withdrawn Phase 4 Interventional

Dopamine D3 Receptor Occupancy in Bipolar Depression

NCT05060549
View directory record Official record
Conditions
Bipolar Depression
Interventions
Cariprazine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 23, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults

NCT00301639
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OROS methylphenidate hydrochloride, methylphenidate hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Jul 23, 2026, 4:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Measuring Brain Activity of School Age Children

NCT03407729
View directory record Official record
Conditions
Perinatal Hypoxia, Dopamine, Neurobehavioral Manifestations
Interventions
Magnetic Resonance Imaging, Cognitive Performance Testing
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
8 Years to 15 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Jul 23, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists

NCT00443872
View directory record Official record
Conditions
Parkinson's Disease
Interventions
orally disintegrating selegiline (Zelapar)
Drug
Lead sponsor
Parkinson's Disease and Movement Disorder Center of Boca Raton
Other
Eligibility
30 Years to 90 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Jul 23, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetics of Disulfiram for Cocaine

NCT00149630
View directory record Official record
Conditions
Cocaine Dependence, Opioid Dependence
Interventions
Disulfiram, Methadone, CBT, Lactose
Drug · Behavioral · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Jul 23, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse

NCT02080819
View directory record Official record
Conditions
Cocaine Dependence
Interventions
levodopa/carbidopa 400/100 BID
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 50 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Jul 23, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

NCT03544229
View directory record Official record
Conditions
Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions
TAK-906 Maleate, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
67
States / cities
Dothan, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Jul 23, 2026, 4:05 AM EDT
Terminated Phase 4 Interventional Results available

L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

NCT03761030
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Depression
Interventions
L-DOPA, Placebo Oral Tablet
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Jul 23, 2026, 4:05 AM EDT
Terminated No phase listed Observational

Characterizing the Effect of Dopamine on Markers of Lymph Re-circulation in Fontan-associated Protein-losing Enteropathy

NCT03322345
View directory record Official record
Conditions
Dopamine, Protein-Losing Enteropathies, Lymphatic System, Lymph, Catecholamine, Single-ventricle, Congenital Heart Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
3 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 4:05 AM EDT
Terminated Phase 2 Interventional

Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI

NCT02148783
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
methylphenidate, Placebo
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Jul 23, 2026, 4:05 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dopamine in Orthostatic Tolerance

NCT00748228
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
dietary sodium
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Jul 23, 2026, 4:05 AM EDT
Terminated No phase listed Observational

SPECT Imaging of DAT Genotype

NCT01492322
View directory record Official record
Conditions
Nicotine Withdrawal
Interventions
TRODAT
Radiation
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Jul 23, 2026, 4:05 AM EDT
Recruiting Phase 3 Interventional

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

NCT06568367
View directory record Official record
Conditions
Excessive Sleepiness, Shift-work Disorder
Interventions
Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
38
States / cities
Cullman, Alabama • Chandler, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 23, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Results available

Switching From Oral Dopamine Agonists to Rotigotine

NCT01976871
View directory record Official record
Conditions
Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease
Interventions
Rotigotine
Drug
Lead sponsor
John Winkelman, MD, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Jul 23, 2026, 4:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System

NCT06261905
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
[11C]-PHNO, Calcitriol, Placebo Control, PET Scan
Drug · Dietary Supplement · Other + 1 more
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 23, 2026, 4:05 AM EDT
Terminated Not applicable Interventional Results available

Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation

NCT04228276
View directory record Official record
Conditions
Stimulant Use Disorder, Substance-related Disorders
Interventions
Repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Jul 23, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

NCT04457310
View directory record Official record
Conditions
Early Course Schizophrenia Spectrum Disorder
Interventions
CVL-562 (PF-06412562) 1 mg, CVL-562 (PF-06412562) 4 mg, CVL-562 (PF-06412562) 15 mg, CVL-562 (PF-06412562) 25 mg, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 23, 2026, 4:05 AM EDT